
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera is expected to see revenue growth from their successful MRD testing, expansion into different clinical areas, and potential FDA approvals, cementing its leadership in the MRD monitoring market and justifying a high valuation and stock price target of $275, although market penetration stagnation remains a risk.
Bears say
Natera is facing competition from other labs and may face challenges in entering new markets, which could impact its revenue and profitability. Additionally, securing FDA approval for precision oncology tests has become increasingly important, and Natera may face challenges in meeting this requirement. Furthermore, there is potential for downside risk due to increasing competition in the emerging MRD landscape and persistent competitive intensity in the Women's Health market. This could impact Natera's ability to achieve its goal of reaching an ASP of $2,000 for its Signatera test.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares